Dec 11 (Reuters) – Lumexa Imaging’s shares rose marginally in their Nasdaq debut on Thursday, valuing the provider of diagnostic imaging services at $1.76 billion.
The IPO market, poised for its strongest year since 2021 after a three-year lull, has regained momentum in recent months despite a disruption caused by the longest U.S. government shutdown in the fall.
Private equity-backed companies have tested the market more this year and have found success as investors remain selective about backing new issuers in mature sectors that offer more predictable revenue.
Lumexa raised $462.5 million in the offering by selling 25 million shares, after pricing at $18.50 per share, the midpoint of its targeted range of $17 to $20.
The diagnostic imaging services provider’s stock opened at $18.65 apiece. It was last trading at $18.74.
The company, backed by private equity firm Welsh, Carson, Anderson & Stowe, delivers diagnostic imaging services such as MRI and CT and runs 184 centers across 13 states, as of September 30.
Barclays, J.P. Morgan and Jefferies were the underwriters of the IPO.
(Reporting by Manya Saini in Bengaluru; Editing by Vijay Kishore)
